Skip to main content
Premium Trial:

Request an Annual Quote

Stephen Fodor, Kevin King

Premium
Affymetrix founder, chairman, and CEO Stephen Fodor will relinquish his CEO responsibilities as of Jan. 1, 2009, the company said last week.
 
Fodor will serve as full-time executive chairman, a position in which he will “identify and advance new platform technologies and explore new market opportunities for the company,” Affymetrix said in a statement.
 
Kevin King, president of Affymetrix, will become CEO and a member of the board of directors on Jan. 1. King joined Affy from Thomson Healthcare in January 2007. Prior to Thomson, he held senior executive positions at GE Healthcare and Global Clinical Systems.
 
Fodor founded Affymetrix in 1993 and served in various roles, including president, chief operating officer, and chief technology officer, until he was appointed CEO in 1997. Fodor has served as chairman of the company’s board since 1999.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.